BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18053198)

  • 41. Low-dose human menopausal gonadotrophin versus clomiphene citrate in subfertile couples treated with intrauterine insemination: a randomized controlled trial.
    Peeraer K; Debrock S; De Loecker P; Tomassetti C; Laenen A; Welkenhuysen M; Meeuwis L; Pelckmans S; Mol BW; Spiessens C; De Neubourg D; D'Hooghe TM
    Hum Reprod; 2015 May; 30(5):1079-88. PubMed ID: 25788569
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis.
    van Wely M; Westergaard LG; Bossuyt PM; van der Veen F
    Fertil Steril; 2003 Nov; 80(5):1086-93. PubMed ID: 14607553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis.
    Agrawal R; Holmes J; Jacobs HS
    Fertil Steril; 2000 Feb; 73(2):338-43. PubMed ID: 10685540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subcutaneously administered Menopur, a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex in subjects undergoing in vitro fertilization.
    Keye WR; Webster B; Dickey R; Somkuti S; Crain J; Scobey MJ
    Reprod Biol Endocrinol; 2005 Nov; 3():62. PubMed ID: 16280073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial.
    Taronger R; Martínez-Cuenca S; Ferreros I; Rubio JM; Fernández-Colom PJ; Martínez-Triguero ML; Pellicer A
    Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():192-197. PubMed ID: 30428403
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial.
    Serafini P; Yadid I; Motta EL; Alegretti JR; Fioravanti J; Coslovsky M
    Fertil Steril; 2006 Oct; 86(4):830-8. PubMed ID: 16963040
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
    Avrech OM; Royburt M; Sabah G; Zukerman Z; Pinkas H; Amit S; Ovadia J; Fisch B
    J Assist Reprod Genet; 1996 May; 13(5):395-400. PubMed ID: 8739055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.
    Wang Y; Kuang Y; Chen Q; Cai R
    Trials; 2018 Aug; 19(1):455. PubMed ID: 30134964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RCT to evaluate the influence of adjuvant medical treatment of peritoneal endometriosis on the outcome of IVF.
    Decleer W; Osmanagaoglu K; Verschueren K; Comhaire F; Devroey P
    Hum Reprod; 2016 Sep; 31(9):2017-23. PubMed ID: 27370359
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM; Humaidan P; Alviggi C
    Hum Reprod; 2021 Jul; 36(8):2157-2169. PubMed ID: 34179973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ANDRO-IVF: a novel protocol for poor responders to IVF controlled ovarian stimulation.
    Bercaire L; Nogueira SM; Lima PC; Alves VR; Donadio N; Dzik A; Cavagna M
    JBRA Assist Reprod; 2018 Mar; 22(1):52-55. PubMed ID: 29303236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Could the addition of hp-hMG and GnRH antagonists modulate the response in IVF-ICSI cycles?
    Requena A; Landeras JL; Martínez-Navarro L; Calatayud C; Sánchez F; Maldonado V; Muñoz M; Fernández M; González A; López S; López R; Pacheco A; Calderón G; Martínez V
    Hum Fertil (Camb); 2010 Mar; 13(1):41-9. PubMed ID: 20384441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome.
    Kan O; Simsir C; Atabekoglu CS; Sonmezer M
    Gynecol Endocrinol; 2019 Oct; 35(10):869-872. PubMed ID: 30973022
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clomiphene citrate is associated with favorable cycle characteristics but impaired outcomes of obese women with polycystic ovarian syndrome undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Medicine (Baltimore); 2017 Aug; 96(32):e7540. PubMed ID: 28796038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial.
    Beguería R; García D; Vassena R; Rodríguez A
    Hum Reprod; 2019 May; 34(5):872-880. PubMed ID: 30927417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles.
    Kuang Y; Hong Q; Chen Q; Lyu Q; Ai A; Fu Y; Shoham Z
    Fertil Steril; 2014 Jan; 101(1):105-11. PubMed ID: 24161646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of HCG in IVF Treatment: Does it depend on age or on protocol?
    Theofanakis C; Athanasiou V; Liokari E; Stavrou S; Sakellariou M; Athanassiou AI; Athanassiou A; Drakakis P; Loutradis D
    J Gynecol Obstet Hum Reprod; 2019 May; 48(5):341-345. PubMed ID: 30794953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
    Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
    Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].
    Wu CX; Zhang T; Shu L; Huang J; Diao FY; Ding W; Gao Y; Wang W; Mao YD; Cui YG; Liu JY
    Zhonghua Fu Chan Ke Za Zhi; 2018 Mar; 53(3):160-166. PubMed ID: 29609229
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation.
    Hazout A; de Ziegler D; Cornel C; Fernandez H; Lelaidier C; Frydman R
    Fertil Steril; 1993 Mar; 59(3):596-600. PubMed ID: 8458463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.